• 18 Dec 2020
• Admin
• News Article

Genosity Enters Into An Agreement With Gemini Therapeutics To Develop A Diagnostic And Implement Testing To Support Geminis Age-Related Macular Degene

Genosity, Inc, A Biotechnology Company Offering Novel Software And Laboratory Solutions To Enable Development And Deployment Of Complex Ngs Assays, Announced An Agreement With Gemini Therapeutics To Conduct Molecular Profiling In Support Of Clinical Trial Patient Selection And Stratification For Gemini&Rsquo;S Gem103 Program In Age-Related Macular Degeneration (Amd).Under This Agreement, Gemini Will Provide Samples From Prospective Patients For Their Clinical Trial For A Customized Next Generation Sequencing Panel, And Genosity Will Use Its Clinical And Technical Expertise To Develop, Clia Validate And Implement The Molecular Assay In Its Clia/Gcp/Glp Laboratory. Genosity Will Then Perform Testing To Support Gemini&Rsquo;S Phase 2A Clinical Trial In Amd To Identify Patients With Defined Molecular Profiles Suitable For Enrollment In The Study. Genosity Is Uniquely Positioned To Offer Custom Assay Development And Implementation For High-Complexity Assays To Biopharma And Biotech Partners, Offering Both Robust Laboratory Meeting Required Regulatory Standards To Support Clinical Trials And A Sophisticated End-To-End Genomics Software Solution To Support Future Commercialization Efforts Across A Range Of Next Generation &Lsquo;Omics&Rsquo; Technologies.Robert Daber, President And Co-Founder Of Genosity Said, &Ldquo;At Genosity, We Make The Complex Possible. Our Unique Expertise And Capabilities Allow Us To Address Complex Clinical Problems And Not Only Help Develop Diagnostic Solutions But Provide A Roadmap For Clinical And Regulatory Implementation. Gemini Is A Leader In Leveraging Molecular Information To Develop Precision Therapeutics In Amd And We Are Excited To Expand Our Testing Menu To Support Another Partner&Rsquo;S Need To Have A Unique Biomarker Test Available For Trial Support.&Rdquo;&Ldquo;Gem103 Has Already Demonstrated Promise In Phase 1 Clinical Studies As A Potential Treatment For Patients With Dry Amd Who Have Complement Factor H Loss Of Function Gene Variants Associated With Their Disease,&Rdquo; Said Jason Meyenburg, Chief Executive Officer Of Gemini Therapeutics. &Ldquo;We Are Pleased To Partner With Genosity, And Look Forward To Leveraging Their High Quality Genetic Sequencing Data As A Means To Advance Not Only Patient Enrollment In Our Phase 2A Regatta Clinical Trial, But The Overall Gem103 Development Lifecycle.&Rdquo;